Strong Dupixent + Vaccines powers upward revision to outlook
30/07/21 -"Sanofi witnessed remarkable growth in Q2, with strong growth in the high-margin Dupixent and Vaccines business being complemented by the recovery in the consumer business. Moreover, the improving ..."
Pages
67
Language
English
Published on
30/07/21
You may also be interested by these reports :
09/01/26
Hikma, over the years, has struggled to create shareholder wealth, perhaps because of its inability (until now) to develop biosimilars on its own. ...
31/12/25
Keeping in mind the underwhelming late-stage results of the immunology drug, amlitelimab, and a few other R&D setbacks in recent years, we have ...
30/12/25
Over the last three years, GSK’s earnings have exceeded the market’s expectations on most occasions. Moreover, the firm’s R&D efforts have yielded ...
19/12/25
The change in the target price is due to a change in the analyst covering the stock, complemented by the usage of systematic intrinsic and peer-based ...